Markets:

Overview

News

Currencies

International

Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

8.070 -0.490 (-5.72%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Top 5 Health Care Stocks That May Plunge In March ↗

March 28, 2024

As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Via Benzinga

SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023 ↗

March 21, 2024

SPRY stock results show that ARS Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024 ↗

March 15, 2024

U.S. equities market is rallying, but there are still interesting investments to make, especially for these strong-buy stocks under $10.

Via InvestorPlace

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

March 07, 2024

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024

March 06, 2024

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Allergic Reaction Focused ARS Pharmaceuticals' Lead Candidate Shows Efficacy In Skin Disorder ↗

February 26, 2024

ARS Pharmaceuticals reports Phase 2 study results for neffy (epinephrine nasal spray) treating chronic spontaneous urticaria. Significant improvements in itch, hives, and erythema scores were observed...

Via Benzinga

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

February 26, 2024

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024

February 22, 2024

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharma Readies Data In Response To FDA's Rejection For Its EpiPen Alternative For Severe Allergic Reactions ↗

February 20, 2024

NAC study results by ARS Pharma comparing neffy (epinephrine nasal spray) to intramuscular injection. Data submission is expected in Q2 2024.

Via Benzinga

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

February 20, 2024

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting

February 05, 2024

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

November 10, 2023

Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported third-quarter financial results.

Via Benzinga

Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging ↗

November 10, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Friday. Shares of Synaptics Incorporated (NASDAQ: SYNA) rose sharply on Friday after the company reported better-than-expected...

Via Benzinga

Topics Stocks

ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates

November 09, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

November 09, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

October 26, 2023

Via ACCESSWIRE

NASDAQ:SPRY Investor Notice: Investigation over Potential Securities Laws Violations by ARS Pharmaceuticals, Inc. ↗

October 11, 2023

San Diego, CA -- (SBWIRE) -- 10/11/2023 -- ARS Pharmaceuticals, Inc. is under investigation on over potential securities laws violations in connection with certain financial statements.

Via SBWire

ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)

October 06, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology

October 03, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 26, 2023

Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi...

Via Benzinga

Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday ↗

September 26, 2023

U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

More Than $8M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying ↗

September 26, 2023

The Dow Jones closed higher by more than 40 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

ARS Pharmaceuticals' EpiPen Alternative Delayed US Approval - Two Analysts Offer Differing Views ↗

September 21, 2023

On Tuesday, The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic...

Via Benzinga

What's Going On With ARS Pharmaceuticals Stock Today? ↗

September 21, 2023

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) shares are trading higher Thursday. The move marks a rebound in the stock following a recent drop in price.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 21, 2023

Via Benzinga

Gold Moves Higher; Fed Leaves Key Overnight Interest Rate Unchanged ↗

September 20, 2023

U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 200 points on Wednesday. The Dow traded up 0.59% to 34,720.69 while the NASDAQ fell 0.07% to 13,668.37. The S&P 500...

Via Benzinga

Topics Economy Stocks

Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

September 20, 2023

Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 20, 2023

Via Benzinga

Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday ↗

September 20, 2023

The company received a Complete Response Letter from the FDA regarding its lead therapy.

Via The Motley Fool

Nasdaq Turns Lower; Cambridge Bancorp Shares Surge ↗

September 20, 2023

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Wednesday. The Dow traded up 0.56% to 34,711.50 while the NASDAQ fell 0.17% to 13,654.54. The S&P 500 also...

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.